Speaking to GeneOnline, Eric Ostertag, CEO of Poseida Therapeutics, said, “Other CAR-T products have not had much success against solid tumors. They have been very successful for liquid tumors, but not outside of it. We are very excited because these results are encouraging not just from the perspective of mCRPC patients or anti-PSMA therapeutics but for CAR-T products, in general, against solid tumors. These are among the best responses ever seen.”

"This innovative Poseida PSMA-directed CAR T cell platform has demonstrated a robust anti-tumor response in patients with metastatic castration resistant prostate cancer” commented Susan F. Slovin, M.D., Ph.D., Associate Vice Chair of Academic Administration at Memorial Sloan Kettering Cancer Center, and investigator on the trial. “This is the first time that I have seen such impressive responses with an immunotherapy product. The responses of my patients in the trial are far beyond my expectations.”